Evidence map›Paper›PMID 35122085›Full record

Trial reportThe Journal of frailty & aging2022

Long-Term Aspirin Use and Self-Reported Walking Speed in Older Men: The Physicians' Health Study.

A R Orkaby, A B Dufour, L Yang, H D Sesso, J M Gaziano, L Djousse, J A Driver, T G Travison

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of frailty & aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Aging and Inflammation.Cold Spring Harbor perspectives in medicine · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A R OrkabyAriela Orkaby, MD MPH, Assistant Professor of Medicine, Harvard Medical School, Geriatric Research, Education and Clinical Center, VA Boston Healthcare System, 150 South Huntington St, Boston, MA 02130, USA, aorkaby@bwh.harvard.edu.
A B Dufour
L Yang
H D Sesso
J M Gaziano
L Djousse
J A Driver
T G Travison

Funding

TUFTS--FIELDINGP30AG031679 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SHALENDER BHASIN · 2008 to 2026
$23.9M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
RANDOMIZED TRIAL OF ASPIRIN AND MORTALITYR01CA040360 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 2002
$775k
Frailty, Statins, and Cardiovascular Disease Burden in Older AdultsR03AG060169 · NIA · HARVARD MEDICAL SCHOOL · PI ORKABY, ARIELA R · 2018 to 2019
$193k
Statins for Primary Prevention of Cardiovascular Disease and FrailtyIK2CX001800 · VA · VA BOSTON HEALTH CARE SYSTEM · PI ORKABY, ARIELA R · 2019 to 2023
–
TRIAL OF ASPIRIN AND BETA-CAROTENE IN U S MD'SR01HL034595 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 1991
–
CSRD VA IK2 CX001800NCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA097193NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595NIA NIH HHS P30 AG031679NIA NIH HHS R03 AG060169
6 · The paper itself

Abstract

backgroundMobility limitation is a component of frailty that shares a bidirectional relationship with cardiovascular disease (CVD). Data are limited on the role of established CVD prevention therapies, such as aspirin, for prevention of frailty and mobility limitation.

objectivesExamine the association between long-term aspirin use and walking speed. DESIGN, SETTING,

participantsProspective cohort of 14,315 men who participated in the Physicians' Health Study I, a completed randomized controlled trial of aspirin (1982-1988), with extended post-trial follow-up. MEASUREMENTS: Annual questionnaires collected data on aspirin use, lifestyle and other factors. Average annual aspirin use was categorized for each participant: ≤60 days/year and >60 days/year. Mobility was defined according to self-reported walking pace, categorized as: don't walk regularly (reference), easy/casual <2mph, normal ≥2-2.9mph, or brisk/very brisk ≥3mph. Propensity scoring balanced covariates between aspirin categories. Multinomial logistic regression models estimated odds of being in each self-reported walking category.

resultsMean age was 70±8 years; mean aspirin use 11 years. There were 2,056 (14.3%) participants who reported aspirin use ≤60 days/year. Aspirin use >60 days/year was associated with drinking alcohol, smoking, hypertension, heart disease and stroke, while ≤60 days/year was associated with anticoagulation use and bleeding history. In all, 13% reported not walking regularly, 12% walked <2 mph, 44% walked ≥2-2.9 mph, and 31% walked ≥3 mph. After propensity score adjustment, regular aspirin use was associated with a faster walking speed. Odds ratios (95% confidence intervals) were 1.16 (0.97 to 1.39), 1.24 (1.08 to 1.43), and 1.40 (1.21 to 1.63) for <2 mph, ≥2-2.9 mph and ≥3 mph, respectively, compared to not walking regularly (p-trend<0.001).

conclusionsIn this cohort of older men, long-term aspirin use is associated with a greater probability of faster walking speed later in life.

Indexed as

PhysiciansWalking SpeedAgedAspirinHumansMaleProspective StudiesSelf ReportAspirinAspirinfrailtygait speedmobility

Identifiers

PMID35122085
PMCPMC8818085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.